BNP Paribas Financial Markets Acquires New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

BNP Paribas Financial Markets purchased a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 23,644 shares of the company’s stock, valued at approximately $41,000.

A number of other hedge funds have also recently made changes to their positions in TSHA. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies during the 4th quarter valued at $8,650,000. Norges Bank bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at about $2,528,000. Avoro Capital Advisors LLC increased its position in shares of Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after buying an additional 1,349,999 shares during the period. B Group Inc. purchased a new position in shares of Taysha Gene Therapies during the fourth quarter valued at about $1,670,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Taysha Gene Therapies during the fourth quarter valued at about $1,520,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 0.4%

Shares of Taysha Gene Therapies stock opened at $2.78 on Wednesday. The company has a market cap of $596.76 million, a price-to-earnings ratio of 4.41 and a beta of 0.90. The company’s 50 day moving average is $1.96 and its 200 day moving average is $1.91. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. During the same period last year, the firm earned ($0.10) earnings per share. Research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Insiders Place Their Bets

In other Taysha Gene Therapies news, major shareholder Paul B. Manning purchased 750,000 shares of the firm’s stock in a transaction on Friday, May 30th. The shares were acquired at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the transaction, the insider now owns 2,841,704 shares of the company’s stock, valued at approximately $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

TSHA has been the topic of several research analyst reports. JMP Securities boosted their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a research report on Thursday, May 29th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective (up previously from $6.00) on shares of Taysha Gene Therapies in a report on Monday. Finally, Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.57.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.